The FTSE 100 dropped 47 points to 6,243 even with good news on vaccines and treatments for COVID-19 from both sides of the Atlantic. Reports of big job cuts at M&S also dampened the mood.
Synairgen () shares almost trebled as it revealed its interferon beta treatment had dramatically reduced the number Covid-19 patients needing intensive care in a UK trial. The drug is inhaled directly into the lungs of people with coronavirus using a nebuliser.
Britain, meanwhile, has ordered 30mln doses of ’s and BioNTech’s new anti-COVID-19 vaccine. No financial details were disclosed.
Future () said trading for its current year is expected to be “towards the top end of market expectations” . The consumer magazine specialist said audience numbers were boosted by a demand for digital media during the pandemic lockdown.
Touchstone Exploration’s () Cascadura project in Trinidad has been confirmed as a significant discovery in a new independent reserves report. Its consultant estimates Cascadura hosts a ‘best’ estimate of 398.5bn cubic feet of gas.
Shanta Gold () says its annualised underlying profits are running at US$100m based on the second quarter. High gold prices and lower costs boosted margins.
Read More: Wobbly FTSE 100 knocked by UK Chinese tensions despite COVID-19 encouragement